UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): August 07, 2026 |
Fulcrum Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
001-38978 |
47-4839948 |
(State or other jurisdiction
of incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
|
|
|
|
|
26 Landsdowne Street |
|
Cambridge, Massachusetts |
|
02139 |
(Address of principal executive offices) |
|
(Zip Code) |
|
Registrant’s telephone number, including area code: (617) 651-8851 |
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s) |
|
Name of each exchange on which registered
|
Common stock, par value $0.001 per share |
|
FULC |
|
Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously disclosed in a current report on Form 8-K filed on June 11, 2026, Greg Tourangeau, Vice President, Finance and principal accounting officer of Fulcrum Therapeutics, Inc., or Fulcrum, mutually agreed with Fulcrum that Mr. Tourangeau will depart from his position at Fulcrum on a date to be agreed. Fulcrum and Mr. Tourangeau have agreed that his tenure in such roles will end on August 7, 2026.
In light thereof, on August 9, 2026, Fulcrum’s Board of Directors appointed Alan Musso, Fulcrum’s chief financial officer and principal financial officer, as principal accounting officer, effective August 7, 2026, upon Mr. Tourangeau’s departure.
Biographical information for Mr. Musso is set forth in Fulcrum’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 30, 2026, and is incorporated herein by reference. Mr. Musso will not receive any additional compensation in connection with this appointment. There is no arrangement or understanding between Mr. Musso and any other persons, respectively, pursuant to which he was appointed as principal accounting officer. There are no family relationships among any of Fulcrum’s directors or executive officers and Mr. Musso, and Mr. Musso does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
FULCRUM THERAPEUTICS, INC. |
|
|
|
|
Date: |
August 10, 2026 |
By: |
/s/ Alex C. Sapir |
|
|
|
Name: Alex C. Sapir
Title: President and Chief Executive Officer |
